These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 17869119)

  • 1. Synthesis and evaluation of chloromethyl sulfoxides as a new class of selective irreversible cysteine protease inhibitors.
    Brouwer AJ; Bunschoten A; Liskamp RM
    Bioorg Med Chem; 2007 Nov; 15(22):6985-93. PubMed ID: 17869119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New peptidic cysteine protease inhibitors derived from the electrophilic alpha-amino acid aziridine-2,3-dicarboxylic acid.
    Schirmeister T
    J Med Chem; 1999 Feb; 42(4):560-72. PubMed ID: 10052963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptidyl beta-homo-aspartals (3-amino-4-carboxybutyraldehydes): new specific inhibitors of caspases.
    Bajusz S; Fauszt I; Németh K; Barabás E; Juhász A; Patthy M; Bauer PI
    Biopolymers; 1999; 51(1):109-18. PubMed ID: 10380358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of cysteine proteases by peptides containing aziridine-2,3-dicarboxylic acid building blocks.
    Schirmeister T
    Biopolymers; 1999; 51(1):87-97. PubMed ID: 10380356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
    Tavares FX; Boncek V; Deaton DN; Hassell AM; Long ST; Miller AB; Payne AA; Miller LR; Shewchuk LM; Wells-Knecht K; Willard DH; Wright LL; Zhou HQ
    J Med Chem; 2004 Jan; 47(3):588-99. PubMed ID: 14736240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
    Dragovich PS; Prins TJ; Zhou R; Webber SE; Marakovits JT; Fuhrman SA; Patick AK; Matthews DA; Lee CA; Ford CE; Burke BJ; Rejto PA; Hendrickson TF; Tuntland T; Brown EL; Meador JW; Ferre RA; Harr JE; Kosa MB; Worland ST
    J Med Chem; 1999 Apr; 42(7):1213-24. PubMed ID: 10197965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of reversible inhibitors of IdeS, a bacterial cysteine protease and virulence determinant.
    Berggren K; Johansson B; Fex T; Kihlberg J; Björck L; Luthman K
    Bioorg Med Chem; 2009 May; 17(9):3463-70. PubMed ID: 19362485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and evaluation of aza-peptide epoxides as selective and potent inhibitors of caspases-1, -3, -6, and -8.
    James KE; Asgian JL; Li ZZ; Ekici OD; Rubin JR; Mikolajczyk J; Salvesen GS; Powers JC
    J Med Chem; 2004 Mar; 47(6):1553-74. PubMed ID: 14998341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aza-peptide epoxides: a new class of inhibitors selective for clan CD cysteine proteases.
    Asgian JL; James KE; Li ZZ; Carter W; Barrett AJ; Mikolajczyk J; Salvesen GS; Powers JC
    J Med Chem; 2002 Nov; 45(23):4958-60. PubMed ID: 12408706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. eta(1)-N-succinimidato complexes of iron, molybdenum and tungsten as reversible inhibitors of papain.
    Rudolf B; Salmain M; Martel A; Palusiak M; Zakrzewski J
    J Inorg Biochem; 2009 Aug; 103(8):1162-8. PubMed ID: 19616302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of cysteine proteases.
    Govardhan CP; Abeles RH
    Arch Biochem Biophys; 1996 Jun; 330(1):110-4. PubMed ID: 8651683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel aza peptide inhibitors and active-site probes of papain-family cysteine proteases.
    Verhelst SH; Witte MD; Arastu-Kapur S; Fonovic M; Bogyo M
    Chembiochem; 2006 Jun; 7(6):943-50. PubMed ID: 16607671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformationally constrained 1,3-diamino ketones: a series of potent inhibitors of the cysteine protease cathepsin K.
    Marquis RW; Yamashita DS; Ru Y; LoCastro SM; Oh HJ; Erhard KF; DesJarlais RL; Head MS; Smith WW; Zhao B; Janson CA; Abdel-Meguid SS; Tomaszek TA; Levy MA; Veber DF
    J Med Chem; 1998 Sep; 41(19):3563-7. PubMed ID: 9733481
    [No Abstract]   [Full Text] [Related]  

  • 14. Synthesis of peptidyl ene diones: selective inactivators of the cysteine proteinases.
    Darkins P; Gilmore BF; Hawthorne SJ; Healy A; Moncrieff H; McCarthy N; McKervey MA; Brömme D; Pagano M; Walker B
    Chem Biol Drug Des; 2007 Mar; 69(3):170-9. PubMed ID: 17441903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of peptidyl-vinylaminophosphonates as novel cysteine protease inhibitors.
    Bhattacharya AK; Rana KC
    Bioorg Med Chem; 2011 Dec; 19(23):7129-35. PubMed ID: 22019466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic studies on the inactivation of papain by epoxysuccinyl inhibitors.
    Meara JP; Rich DH
    J Med Chem; 1996 Aug; 39(17):3357-66. PubMed ID: 8765519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Racemic and chiral sulfoxides as potential prodrugs of 4-pyrone COX-2 inhibitors.
    Caturla F; Amat M; Reinoso RF; Calaf E; Warrellow G
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3605-8. PubMed ID: 16647258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies.
    Dragovich PS; Webber SE; Babine RE; Fuhrman SA; Patick AK; Matthews DA; Reich SH; Marakovits JT; Prins TJ; Zhou R; Tikhe J; Littlefield ES; Bleckman TM; Wallace MB; Little TL; Ford CE; Meador JW; Ferre RA; Brown EL; Binford SL; DeLisle DM; Worland ST
    J Med Chem; 1998 Jul; 41(15):2819-34. PubMed ID: 9667971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 1,4-naphthoquinone scaffold in the design of cysteine protease inhibitors.
    Valente C; Moreira R; Guedes RC; Iley J; Jaffar M; Douglas KT
    Bioorg Med Chem; 2007 Aug; 15(15):5340-50. PubMed ID: 17532221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies.
    Dragovich PS; Webber SE; Babine RE; Fuhrman SA; Patick AK; Matthews DA; Lee CA; Reich SH; Prins TJ; Marakovits JT; Littlefield ES; Zhou R; Tikhe J; Ford CE; Wallace MB; Meador JW; Ferre RA; Brown EL; Binford SL; Harr JE; DeLisle DM; Worland ST
    J Med Chem; 1998 Jul; 41(15):2806-18. PubMed ID: 9667970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.